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Vhe advances in cardiac electrophysiology during 2003 will
e divided into three basic categories: mechanisms, genetics,
nd therapy, the latter including ablation, devices, drugs, and
unique pacing application in heart failure. This brief
ummary is not a comprehensive review article, and cannot
o justice to all the efforts and many publications by
utstanding clinical and basic investigators. To those whose
ork is not mentioned, I apologize in advance. I have
imited most references to 2003, with occasional exceptions.
ECHANISMS
robably the major recent advance in our understanding of
linical cardiac arrhythmias is the recognition that the
ulmonary veins play a role in the initiation of atrial
achyarrhythmias, particularly atrial fibrillation (AF). Al-
hough interest in the electrophysiology of the thoracic veins
ates back many years (1), Haissaguerre et al. (2) opened a
ew chapter on mechanisms of atrial arrhythmias. Since
hen, multiple groups have demonstrated initiation of AF
rom pulmonary veins (3), which may have larger diameters
4) and be associated with larger left atria (5), than in
atients without AF. Most of the foci responsible for AF
ppear to come from the upper pulmonary veins and are
stial in location (6).
The mechanisms responsible for pulmonary vein depo-
arization are still being investigated, but may include early
fterdepolarizations (7) and re-entry (8). Even the vein of
arshall and the venae cavae may be sources of ectopic
ischarge provoking AF (9). In the latter study, of 240
atients with 358 ectopic foci initiating paroxysmal AF, 68
ad AF initiated by foci discharging in the left atrium,
uperior vena cava, crista terminalis, ligament of Marshall,
nteratrial septum, and coronary sinus ostium.
Once initiated, the maintenance of AF may depend on
he periodic activity of a small number of rotors located in
he posterior left atrial wall near the pulmonary veins.
xperimental data suggest that these rotors activate the atria
apidly to produce fibrillatory conduction that propagates
rom the left to the right atrium and may help explain the
uccess of ablation in and around the pulmonary veins (see
he following text) (10).
Animal studies often presage subsequent clinical obser-
From the Krannert Institute of Cardiology, Indiana University School of Medicine
nd the Roudebush Veterans Administration Medical Center, Indianapolis, Indiana.
upported in part by the Herman C. Krannert Fund, by grant HL 52323 from the
ational Heart, Lung, and Blood Institute of the National Institutes of Health.iManuscript received January 14, 2004; accepted January 27, 2004.ations. Ausma et al. (11) demonstrated in the goat that AF
aused remodeling of electrophysiologic, contractile, and
tructural atrial properties, subsequently replicated by many
nvestigators in humans. Elvan et al. (12) showed that
hronic AF impaired sinus node function in dogs with
eversal after cessation of AF. Recently, Hocini et al. (13)
emonstrated reverse remodeling of sinus node function
fter radiofrequency ablation of AF in patients who had
ymptomatic sinus pauses exceeding 3 s on termination of
aroxysmal AF. Satoh and Zipes (14) in dogs found that
esium induced early afterdepolarizations triggering a poly-
orphic atrial tachycardia and suggested the possibility of
trial torsade de pointes occurring in patients with long QT
yndrome. Subsequently, Kirchhof et al. (15), using
onophasic action potential recordings, demonstrated a
imilar phenomenon in patients with the long QT syn-
rome.
Finally, although not an electrophysiologic mechanism, it
s important to consider recent data suggesting that throm-
ogenesis in AF may not result solely from left atrial
emostasis. Recent data suggest that AF can alter the
xtrinsic coagulation pathway. Tissue factor expression is
verexpressed in the endothelia of atrial tissue in patients
ith non-valvular AF, particularly those containing inflam-
atory cells and denuded matrix. These changes may be
nvolved in the pathogenesis of thrombosis in patients with
on-valvular AF (16).
entricular tachyarrhythmias. Understanding mecha-
isms of ventricular tachyarrhythmias has also progressed.
ignificant research has centered on the restitution proper-
ies of the heart. These represent the dynamic dependence
f action potential duration (APD) or conduction velocity
n the previous diastolic interval (17). The restitution
ypothesis (18) is based on the concept of a steep APD
estitution slope as a primary dynamic factor predisposing
ropagating cardiac waves to break up and cause ventricular
brillation (VF). Flattening this curve might suppress the
bility to develop VF. Adrenergic agonists can steepen the
PD restitution curve and may be related to the known
ffects of adrenergic stimulation in facilitating VF (19). Two
ypes of VF have been demonstrated in isolated perfused
abbit hearts. The first type of VF is associated with steep
PD restitution and normal excitability but, because of
cute global ischemia, the APD restitution curve can flatten
nd decrease excitability, converting it to the second type of
F. The latter might occur when acute or chronic regionalschemia precedes the onset of VF. Chen et al. (17)
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April 7, 2004:1306–14 Year in Electrophysiologyostulate that type 1 VF may be present in a non-ischemic
rea with type 2 VF in the ischemic zone, a combination
nlikely to self-defibrillate and possibly more difficult to
efibrillate by electrical shocks. Conversely, spontaneous
ermination of VF might be facilitated by acute global
schemia that flattens the APD restitution while providing a
rief window of opportunity for self-defibrillation before
rogressive ischemia converts type 1 to lethal type 2 VF
wing to reduced excitability. However, other studies have
emonstrated that a single, rapidly firing re-entrant scroll
ave or rotor may underlie VF (20).
Understanding mechanisms responsible for VF will be
ritical for the development of future drug interventions.
ut, at the present time, no antiarrhythmic drug, except
ossibly amiodarone, based on a meta-analysis (21), impacts
avorably on VF and sudden cardiac death. In fact, it is the
rugs that affect “upstream” cardiac events provoking the
lectrical instability (e.g., ischemia, fibrosis) leading to VF (22),
ncluding aspirin, beta-blockers, angiotensin-converting en-
yme inhibitors, spironolactone, fish oil, and statins, which
ave had a major impact on mortality. Hypercholesterol-
mia in rabbits produces proarrhythmic neural and electrical
emodeling (23), while lipid-lowering drugs reduced the
azard for ventricular tachycardia (VT)/VF recurrence in
mplantable cardioverter-defibrillator (ICD) patients who
ere part of the Antiarrhythmics Versus Implantable De-
brillators (AVID) trial. Perhaps statins have a direct
nti-arrhythmic effect (24).
rugada syndrome. We now know that there are multiple
ypes of VT, some of which have very distinct mechanisms
f origin. For example, the Brugada syndrome is thought to
e due to early repolarization of right ventricular epicar-
ium, with loss of action potential dome at some epicardial
ites but not others. The resulting transmural dispersion of
epolarization can lead to conduction of the action potential
ome from sites at which it is maintained to sites where it
s lost, inducing phase 2 re-entry and a closely coupled
xtrasystole that triggers a ventricular tachyarrhythmia due
o re-entry (25). Prolongation of the QT interval in the
ight precordial leads may be consistent with that hypothesis
26). In these patients, sodium channel blockade can induce
ypical electrocardiographic (ECG) changes and VT (27). A
ariety of provocations, including temperature and other
rugs, have been demonstrated to provoke the typical ECG
hanges.
ong QT syndrome. The long QT syndrome is thought to
esult from an increase in transmural dispersion of repolariza-
ion and the development of early afterdepolarization-induced
riggered activity that provokes a ventricular extrasystole.
he latter, interacting with the dispersed repolarization, can
hen cause a VT sustained by re-entry. Preferential prolon-
ation of M-cell APD can contribute to an increase in the
T interval as well as the dispersion (25).
atecholaminergic polymorphic VT. Catecholaminergic
olymorphic VT appears to result from abnormalities in
yanodine receptors, which are responsible for release of yalcium from the sarcoplasmic reticulum in response to
alcium entry. The exact electrophysiologic mechanism
esponsible for the VT, which often takes the form of
idirectional VT, is still under investigation, but probably
elates in some fashion to increased calcium release (28).
rrhythmogenic right ventricular cardiomyopathy. Ar-
hythmogenic right ventricular cardiomyopathy is character-
zed by fibrofatty replacement of cardiomyocytes, beginning
rimarily in the right ventricle, but in more advanced stages
nvolving the left ventricle and intraventricular septum (29).
lectroanatomic mapping in some patients demonstrate
Ts consistent with a re-entrant mechanism.
ommotio cordis. Link et al. (30) have performed a series
f studies in juvenile swine demonstrating the mechanism
y which chest wall impact during the ventricular vulnerable
eriod can provoke VF. This can help explain sudden death
uffered by young athletes when struck with hockey pucks,
aseballs, and other objects.
ENETICS
he concept that cardiac arrhythmias might have a genetic
asis, although not new, accelerated rapidly with the map-
ing of the first long QT gene to the short arm of
hromosome 11 (31). However, it is important to stress that
single clinical phenotype may be caused by different
enetic substrates, while a single gene can cause very
ifferent phenotypes by acting through different pathways
32).
In the past several years we have gained insight into a
roup of electrophysiologic diseases previously included
nder the heading of primary electrical disease. When VF
ccurred, it was often called “idiopathic.” However, we now
ealize that molecular abnormalities in ion channels or their
upporting elements cause many (and most probably, ulti-
ately, most) of these diseases. Ion channels consist of
roteins and glycoproteins that form pores across the
embrane permitting ions to flow, causing a voltage change
cross the membrane responsible for the propagated action
otential. Multiple currents produced by sodium, potas-
ium, calcium, chloride, and other ions can become abnor-
al and create the substrate for the development of cardiac
rrhythmias. The following will only briefly elucidate major
onopathies, highlighting advances in the past year.
ong QT syndrome. The long QT syndrome represents
he first of these ionopathies to have a genetic basis
stablished. Presently, seven genotypes caused by mutations
n six genes affecting the cardiac potassium currents, IKr and
Ks, and sodium inactivation, as well as an anchoring protein
alled ankryn-B, can be responsible for the long QT
yndrome. Mutations in ankyrin-B, an abnormality that
nterrupts normal sodium and calcium function, appears as
possible cause for LQT4 (33). Because these ionopathies
ccount for perhaps 50% to 60% of the patients with long
T syndrome, it is clear that additional abnormalities haveet to be determined. It is known that patients with
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Year in Electrophysiology April 7, 2004:1306–14utations in the pore region of the HERG (LQT2) gene
ave a significantly higher risk of cardiac events than
ubjects with mutations in the non-pore region. However,
his does not appear to hold true for patients with LQT1
34). An epinephrine challenge can help establish the ECG
iagnosis in patients with LQT1 mutation carriers with
Tc  460 ms (35). This may be important because “silent
arriers” of the congenital long QT syndrome may develop
ignificant QT prolongation when exposed to drugs that in
rdinary circumstances produce only minimal QT
rolongation.
An approach to risk stratification based on the locus of
he causative mutation affects the clinical course of long QT
atients and modulates the effects of the QTc and gender on
linical manifestations. For example, the incidence of a first
ardiac event before the age of 40 years and before the
nitiation of therapy was lower among patients with a
utation at the LQT1 locus (30%) than among those with
mutation at the LQT2 locus (46%) or those with a
utation at the LQT3 locus (42%). Genetic locus and QTc,
ut not gender, were independent predictors of risk. QTc
as an independent predictor of risk among patients with a
utation at LQT1 locus and those with a mutation at
QT2 locus but not among those with a mutation at LQT3
ocus, whereas gender was an independent predictor of
vents only among those with LQT3 location (36).
Sinus bradycardia in LQT3 patients may result from
odium channel mutations displaying a persistent inward
urrent or a negative shift in inactivation, leading to sinus
auses or arrest (37).
Autoantibodies may also play a role in some long QT
atients, as demonstrated in rabbits (38) and in patients
39). The latter patient had autoantibodies against the
ERG channel, which reduced IKr and prolonged APD.
In the future, it may be possible to genetically treat
atients with the long QT syndrome. A transgenic mouse
ith a long QT phenotype (Kv1DN) created by overexpres-
ion of a truncated potassium channel in the heart was
ested to determine whether direct injection of adenoviral
ectors expressing wild-type Kv1.5 (AV-Kv1.5) into the
yocardium would correct the QT. Overexpression of the
v1.5 reconstituted a 4-aminopyridine-sensitive outward
otassium current associated with shortening of ventricular
PD, elimination of early afterdepolarizations, a shortened
T interval, decreased dispersion of repolarization, and
ncreased heart rate (40).
hort QT syndrome. Another abnormality, short QT
yndrome (corrected QT 300 ms), contrasts with the long
T syndrome in that these individuals have a short QT
nterval, and ventricular refractory period, and at least some
f them have abnormalities of cardiac IKr (KCNH 2). The
utations increase IKr, leading to heterogeneous abbrevia-
ion of APD and refractoriness. This gain of function
utation can cause death in infants and may be linked tohe sudden infant death syndrome (41). There is a high risk wf sudden death in young, otherwise healthy, individuals
42).
ndersen’s syndrome. Mutations in KCNJ2 encoding
ir2.1 or IK1 channels recently have been linked to long
T 7, which is known as Andersen’s syndrome (43). This
are autosomal-dominant inherited disorder is characterized
y physical abnormalities including short stature, scoliosis,
ateral or medial deviation of one or more fingers, hyperte-
orism, low-set or slanted ears, micrognaphia, and broad
orehead, as well as periodic paralysis, cardiac arrhythmias,
nd long QT.
rugada syndrome. Brugada syndrome (44), characterized
y an accentuated J-wave primarily in V1 to V3, with
T-segment elevation, often followed by a negative T-wave
nd an R prime, may be the cause of sudden unexplained
eath syndrome, especially in those from many southeast
sian countries. It is an autosomal-dominant mutation in
he SCN5A gene encoding for the alpha subunit of the
ardiac sodium channel, with almost 60 different mutations
emonstrated (25). Individuals with Brugada syndrome and
o previous cardiac arrests may have a high risk of sudden
eath if they have inducibility of ventricular arrhythmias
nd a previous history of syncope (45). Hyperthermia can
nmask the Brugada ECG pattern in the SCN5A-H681P
utation (46). The mutation in SCN5A results in loss of
unction due to failure of the sodium channel to express a
hift in voltage and time dependence of sodium activation,
nactivation, or reactivation; entry of the sodium channel
nto an intermediate state of inactivation from which it
ecovers more slowly; or accelerated inactivation of the
odium channel (25). Brugada patients can display fever-
nduced polymorphic VT, and a host of agents can unmask
he Brugada syndrome or lead to accentuation of ST-
egment elevation (25).
atecholaminergic polymorphic VT. Defects in the ryan-
dine receptor (RyR2) on the sarcoplasmic reticulum, re-
ponsible for the release of calcium required for muscle
ontraction, may cause this syndrome. “Leaky” ryanodine
hannels can trigger fatal cardiac arrhythmias and provide a
ossible explanation for catecholaminergic polymorphic VT
47). The mutant RyR2, found in patients with cat-
cholaminergic polymorphic VT, has decreased calstabin2
inding affinity, which can trigger ventricular arrhythmias
nd sudden cardiac death after stress and exercise (48).
utations of calsequestrine2 may also cause catecholamin-
rgic polymorphic VT and appear to be less common (49).
ymptomatic patients have a poor prognosis unless treated
ith an ICD (50).
amilial AF. Familial AF due to abnormalities in
CNQ1, also responsible for the LQT1 syndrome. This is
he first gene to be linked to familial AF (51). This gain of
unction mutation appears to be responsible for AF by an
nknown mechanism. It is likely that more genes may be
esponsible for, or contribute to, the development of AF
52). Chen et al. (51) identified a four-generation family
ith autosomal-dominant hereditary AF without structural
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April 7, 2004:1306–14 Year in Electrophysiologyeart disease. The QT interval was prolonged but there was
o sudden death. Thus, in contrast to the long QT-
ssociated mutations in KCNQ1, which all have a dominant
egative effect, the AF-associated KCNQ1 mutation leads
o a gain of potassium channel function and may produce
F by reducing APD and effective refractory period in atrial
yocytes.
radyarrhythmias. Progressive familial heart block has
een described in association with mutations in SCN5A. It
ppears to be an autosomal-dominant disease of the cardiac
onduction system, one form occurring early and progress-
ng rapidly while affecting primarily the bundle branches
nd a second form occurring later in life and affecting
rimarily the atrioventricular node. In a French family with
5 potentially affected members, 25 individuals were carriers
f the SCN5A mutation and exhibited various types of
onduction defects involving the P-wave, PR interval, and
RS duration, all progressing with age. These findings
emonstrate that the hereditary disease described by Le-
egre is caused by a haploinsufficiency mechanism, which in
ombination with age, leads to progressive alteration in
onduction velocity (53).
Atrial standstill has been associated with the SCN5A
ene (54) as well as changes consistent with dilated cardio-
yopathy and severe degenerative abnormalities of the
onduction system (55). The sodium channel mutations
ay also produce sinus node dysfunction in LQT3 families
37). A novel mutation in SCN5A and rare polymorphisms
n the atrial specific connexin40 gene may be responsible for
trial standstill (54).
rrhythmogenic right ventricular cardiomyopathy.
inkage analysis previously mapped the involved gene to
hromosome 14Q24.3, whereas the present study confirms
hat locus and failed to detect causative mutations in exonic
equences of four genes (56). First- and second-degree
elatives of patients with arrhythmogenic right ventricular
ardiomyopathy have a high percentage of people who are
imilarly affected (57), further supporting a genetic origin.
Naxos disease is a recessively inherited form of arrhyth-
ogenic right ventricular cardiomyopathy in which the
ardiac phenotype is associated with palmoplantar kerato-
erma and woolly hair. Thus, this form of the disease is a
eart muscle disorder with distinctive physical characteris-
ics (58). It may be caused by a deletion in plakoglobin (59).
olff-Parkinson-White (WPW) syndrome. This well-
nown and well-characterized electrophysiologic disorder
as been created in transgenic mice by overexpressing an
sn488Ile mutant [(TG) N488I] human PRKAG2 com-
lementary deoxyribonucleic acid. The transgenic mice
ecapitulate an electrophysiologic phenotype similar to hu-
ans with WPW syndrome (60). They exhibit a
rocainamide-sensitive, adenosine-resistant, accessory path-
ay. Mutations in this gene produce an unusual human
ardiomyopathy characterized by ventricular hypertrophy
nd electrophysiologic abnormalities consistent with WPW
yndrome, along with progressive degenerative conduction iystem disease. PRKAG2 mutations create a glycogen
torage cardiomyopathy, which provides an anatomic expla-
ation for the electrophysiologic findings, and implicate
isruption of the annulus fibrosis by glycogen-engorged
yocytes, as the cause of pre-excitation in Pompe, Danon,
nd other glycogen storage diseases. These findings are
onsistent with the original identification of a genetic defect
s a missense mutation in the gene that encodes the gamma
regulatory subunit of PRKAG2. The mutation results in
he substitution of glutamine for arginine at residue 302 in
he protein (61). It has not been established that these
olecular abnormalities are responsible for sporadic WPW
yndrome (62).
HERAPY
blation. One of the most exciting applications of radio-
requency catheterization ablation has been in patients with
F. After the Haissaguerre et al. (2) observation, a number
f investigators have pursued various techniques in ablating
ocal discharge originating in pulmonary veins (63). Pap-
one et al. (64) developed a technique for anatomic pulmo-
ary vein isolation and demonstrated the superiority of this
pproach over medical therapy for recurrence of AF and
ll-cause mortality and morbidity resulting from heart
ailure and ischemic cerebrovascular events. Quality-of-life
ssessment reached normal values in contrast to medically
reated patients. The success rate using circumferential left
trial ablation was approximately 85% in patients who had
aroxysmal or chronic AF at a mean of 900 days after
blation.
Circumferential left atrial ablation strategy is significantly
ore effective than segmental ostial ablation, with success
ates at 6 months of 87% and 67%, respectively. The average
rocedure duration with both approaches was approximately
.5 h (65). Major potential side effects include pulmonary
ein stenosis and pericardial tamponade. Pulmonary vein
tenosis can occur in 15% to 20% of pulmonary veins,
epending on the particular technique used (66) and how
tenosis is diagnosed.
The pulmonary veins appear to be more important in
aroxysmal or possibly persistent AF rather than a chronic,
ustained AF, where ablation may be successful in only a
ne-quarter of patients (63).
Radiofrequency catheterization ablation of virtually all
ther supraventricular tachycardias is now relatively routine,
hough challenges remain in some patients, such as those
ith hard to locate accessory pathways, congenital heart
isease, and after cardiac surgery (63). It is of interest that a
ecent trial of 224 eligible patients with asymptomatic
PW syndrome randomly assigned 37 patients to radio-
requency catheter ablation of the accessory pathways and
5 patients to no treatment. Two patients in the ablation
roup (5%) and 21 in the control group (60%) had arrhyth-
ic events, with 1 control patient presenting with VF. Thencidence of arrhythmic events was 7% among patients who
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Year in Electrophysiology April 7, 2004:1306–14nderwent ablation and 77% among control patients, with a
isk reduction with ablation of 92%. The study challenges
he notion that risks of ablation in the asymptomatic WPW
atient may be comparable to the risk of a life-threatening
rrhythmia (67). Risk stratification in WPW patients by
lectrophysiologic testing may be useful as well (68).
New catheter approaches, including a magnetic guidance
ystem in which a magnetic field can be used to guide the
atheter, are being explored (69). In addition, new catheter
esigns, as well as alternative energies, including cryoabla-
ion and high-intensity focused ultrasound, are being tested
63). Newer mapping systems are capable of improving
uccess rates and reducing fluoroscopy time (70). One
pproach includes an electromagnetic catheter positioning
ystem that can be superimposed on other images such as
hose obtained with magnetic resonance, computer tomog-
aphy, or fluoroscopy that have been previously acquired
71). Ablation procedures can also be performed intraoper-
tively (72).
Advances in the application of ablation to patients with
entricular tachyarrhythmias include elimination of prema-
ure ventricular complexes that may trigger ventricular
achyarrhythmias, including VF (73,74). Ventricular tachy-
ardia can be ablated from either ventricular outflow tract,
ncluding the valve cusps and in the epicardium (75) in
atients without or with coronary artery disease. The
picardial origin of VTs may be responsible for some failures
f endocardial ablation (76).
EVICES
e have all become used to, and even perhaps complacent
ith, the fundamental reliability of implantable pacemakers
nd ICDs. Recent advances have been the development of
acemakers and ICDs to monitor comorbidities, such as
eart failure, and their increasing application to include
roader groups of patients (see section entitled “Heart
ailure” in the following text). It is now clear that the ICD
ecreases the risk of arrhythmic deaths and all-cause mor-
ality, the extent related to the underlying risk of
rrhythmia-related death relative to competing causes (77).
The study perhaps raising the most interest and discus-
ion was the Multicenter Automatic Defibrillator Implan-
ation Trial II (MADIT II) (78), which demonstrated the
mproved survival with an ICD compared with conventional
herapy in patients with previous myocardial infarction and
jection fraction of 30% or less. The mortality rates were
9.8% in the conventional therapy group and 14.2% in the
efibrillator group with a hazard ratio for risk of death from
ny cause in the defibrillator group compared with conven-
ional therapy of 0.69. The application of ICD implantation
n this large group of patients has major medical and
conomic implications.
The Dual Chamber and VVI Implantable Defibrillator
DAVID) trial determined the efficacy of dual-chamber
acing compared with backup ventricular pacing in patients eith standard indications for ICD implantation but without
n indication for bradycardia pacing. Five hundred six
atients were randomly assigned to have ICDs programmed
o backup ventricular pacing at 40 beats/min (VVI) or
ual-chamber rate-responsive pacing at 70 beats/min
DDDR). The authors found that one-year survival free of
he composite end point of death or hospitalization for heart
ailure was 84% for patients treated with VVI pacing at a
ate of 40 compared with 73% for patients treated with
DDR pacing at a rate of 70, yielding a relative hazard of
.61. It was concluded that dual-chamber pacing offered no
linical advantage over ventricular back-up pacing and may
e detrimental. Some have interpreted the results of this
tudy to indicate that right ventricular apical pacing is
otentially harmful, which may be true. However, an often
verlooked fact is that the patients receiving DDDR pacing
ad a minimum rate of 70 beats/min 24 h per day and,
herefore, in this population it is possible that the continued
ate of 70 beats/min was detrimental, over and above the site
f right ventricular apical pacing (79).
The Defibrillator Versus Beta Blockers for Unexplained
eath in Thailand (DEBUT) trial randomized patients
ith sudden unexplained death syndrome to beta-blockers
r an ICD. During a three-year follow-up, there were four
eaths in the beta-blocker group, whereas seven subjects in
he ICD arm had recurrent VF effectively treated by the
CD. When the main and pilot study data were combined,
here were 7 deaths in the beta-blocker group and none in
he ICD group, with 12 ICD patients receiving ICD
ischarges owing to recurrent VF (80). Implantable
ardioverter-defibrillators have been shown beneficial in
igh-risk long QT patients (81), patients with right ven-
ricular cardiomyopathy (82), and those with hypertrophic
ardiomyopathy (83). The latter may be stratified by a
istory of cardiac arrest, spontaneous sustained VT, family
istory of sudden hypertrophic cardiomyopathy-related
eath, syncope, non-sustained VT, abnormal blood pressure
esponse with exercise, or extreme left ventricular hypertro-
hy.
T-wave alternans may help define the patient who will
enefit from ICD implantation. Among patients with
revious myocardial infarction and left ventricular ejection
raction of 30% or less, those without microvolt T-wave
lternans had no sudden death or cardiac arrest, compared
ith an event rate of 15.6% among the remaining patients
84). Similarly, patients with dilated ischemic cardiomyo-
athy can be stratified by the presence of microvolt T-wave
lternans as well as baroreflex sensitivity to identify those at
isk of life-threatening ventricular arrhythmia for whom an
CD might be beneficial (85).
A remaining issue with the ICD is its usefulness as
rimary prevention of sudden cardiac death in patients with
on-ischemic dilated myopathy. Published data have pro-
uced conflicting results. In a recent trial of 103 patients
ith non-ischemic dilated cardiomyopathy, left ventricularjection fraction 35%, non-sustained VT, mortality and
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April 7, 2004:1306–14 Year in Electrophysiologyuality of life in patients treated with amiodarone or an ICD
ere not statistically different (86). However, the Sudden
ardiac Death-Heart Failure Trial (SCD-HeFT) results
ill be known shortly and hopefully will provide definitive
nformation.
The Public Access Defibrillation (PAD) trial was a
rospective trial, multicenter, randomized clinical study
esting whether volunteer non-medical responders could
mprove survival from out-of-hospital cardiac arrest by
sing automated external defibrillators. As presented at the
ast American Heart Association meeting, survival almost
oubled with the use of PAD (87). Importantly, patients
esuscitated from out-of-hospital cardiac arrest with early
efibrillation have long-term survival similar to that among
ge-, gender-, and diseased-matched patients who did not
ave out-of-hospital cardiac arrests. The quality of life
mong the majority of survivors is similar to that of the
eneral population (88).
RUGS
ne of the potential reasons for the lack of difference
etween rate and rhythm control in the Atrial Fibrillation
ollow-up Investigation of Rhythm Management (AF-
IRM) may be the inadequacy of presently available drugs
o maintain sinus rhythm. One new approach for atrial
rrhythmias is to target an ion channel found in the atrium
nd not in the ventricle. A novel potassium channel blocker,
VEO118, has been demonstrated in pigs to prolong atrial
ffective refractory period and prevent atrial arrhythmias
ith no apparent action on ventricular repolarization. This
rug blocks the molecular basis for the human cardiac
ltrarapid delayed rectifier potassium current (IKur) and the
ransient outward current (89). Potassium channel gene,
CNA5, whose expression underlies the ultra IKur, is also
xpressed in extra-cardiac tissues so that extra-cardiac ad-
erse effects might arise (90).
At the recent American Heart Association meeting
April 2, 2003), Halperin (91) reported the results of the
hird Stroke Prevention Oral Thrombin Inhibitor in Atrial
ibrillation (SPORTIF-III) trial, which demonstrated that
imelagatran treatment compared with warfarin was asso-
iated with a lower incidence of stroke and of major
omplications other than a transient elevation of liver
nzymes.
EART FAILURE
he Multicenter InSync Randomized Clinical Evaluation
mplantable Cardioverter Defibrillator (MIRACLE ICD)
rial examined the efficacy and safety of combined cardiac
esynchronization therapy (CRT) and ICD therapy in 369
atients with ventricular ejection fraction of 35% or less and
RS duration of 130 ms, who were at high risk for
ife-threatening ventricular arrhythmias and in New York
eart Association functional class III or IV. A total of 182atients were randomized to receiving ICD activated butRT off, and 187 receiving ICD activated and CRT on. At
ix months, patients assigned to CRT had greater improve-
ent in median quality-of-life score and New York Heart
ssociation functional class compared with control subjects.
eak oxygen consumption increased, as did treadmill exer-
ise duration, but 6-min walk did not. The authors con-
luded that CRT improved quality of life, functional status,
nd exercise capacity in these patients (92).
Bristow presented the results of the Comparison of
edical Therapy, Pacing, and Defibrillation in Chronic
eart Failure (COMPANION) trial on March 31, 2003,
hich randomized 1,520 patients with moderate to severe
eart failure to receive standard medical therapy, CRT, or
RT plus an ICD. Over a median follow-up of 14 months,
he CRT groups had fewer hospitalizations and improved
ymptoms. In addition, the CRT plus ICD group showed
ore than a 40% reduction in mortality (93).
Cardiac resynchronization therapy not only improves
unctional status but also can result in improved systolic and
iastolic function, and decreased mitral regurgitation pos-
ibly by reverse left ventricular remodeling (94). However,
aution is needed because left ventricular epicardial pacing
an at times cause a ventricular arrhythmia (95,96).
A new approach in heart failure patients to increase
entricular contractility is to apply electric currents during
he refractory period. Very early data suggest an improve-
ent in cardiac contractility (97).
ONCLUSIONS
t is clear, from the synopsis presented in this review, that
he past year has witnessed striking advances in both our
nderstanding and treatment of cardiac arrhythmias. Major
hallenges remain, particularly in patients with atrial fibril-
ation and ventricular tachyarrhythmias. No doubt, this
ollowing year will bring further progress in our attempts to
elp these patients.
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